Prussian blue-coated magnetic nanoparticles for …
Manganese-containing Prussian blue nanoparticles for ..
Our rationale for pursuing nanoparticles is that they offer unique advantages that can be harnessed for molecular imaging of PBTs, including: small sizes (~10–200 nm) that enable the nanoparticles to easily penetrate body barriers and extravasate across the leaky tumor vasculature of PBTs (via the enhanced permeability and retention effect, on account of the abnormal molecular and fluid transport dynamics of these tumors);– high surface area-to-volume ratios that enable attachment of PBT-targeting ligands with high density; and the ability to be visualized via imaging modalities such as MRI or fluorescence.– There are numerous examples in the literature of nanoparticles being used for the imaging and treatment of a variety of cancers, including gold nanoparticles/nanorods/nanoshells, iron oxide nanoparticles, carbon nanotubes, dendrimers, polymer-based nanoparticles, and quantum dots.– While a few of these nanoparticles are currently undergoing clinical evaluation,,– their use for molecular imaging of PBTs has been limited, thereby representing an opportunity for the field of nanomedicine.
Example 1 Synthesis of Prussian Blue Nanoparticles Each Utilizing ..
Over the past decade, technological progress made in the field of molecular biology coupled with increased access to tissue samples from PBT patients (obtained via biopsy and/or autopsy) and the development of relevant animal models have improved our understanding of the underlying molecular biology of PBTs., However, thus far, there are no clinically approved, molecularly-specific imaging agents for PBTs, which can be primarily attributed to the challenges of working in the brain and central nervous system, including crossing the blood–brain barrier and penetrating the brain parenchyma. In this paper, we describe a manganese-containing Prussian blue (MnPB) nanoparticle for multimodal molecular magnetic resonance imaging (MRI) and fluorescence-based imaging of PBTs.